Quidel

News Release

Printer Friendly Version View printer-friendly version << Back
July 9, 2009 at 8:02 AM EDT

Quidel to Hold 2009 Second Quarter Conference Call on July 22, 2009

SAN DIEGO--(BUSINESS WIRE)--Jul. 9, 2009-- Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, will release 2009 second quarter financial results after market close on Wednesday, July 22, 2009.

Following the release of the results, Douglas C. Bryant, president and chief executive officer, and John M. Radak, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. ET (2:00 p.m. PT) to discuss those results and to answer questions.

To participate in the live call by telephone from the U.S., dial (866) 804-6929, or from outside the U.S. dial (857) 350-1675, and enter the passcode 75533425.

A live webcast of the call can be accessed at www.quidel.com, and the Web site replay will be available for 14 days. The telephone replay will be available for 48 hours beginning at 8:00 p.m. ET (5:00 p.m. PT) on July 22 by dialing (888) 286-8010 from the U.S., or (617) 801-6888 for international callers, and entering passcode 34814682.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue®, Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel'sSpecialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment have an impact on clinical outcomes and provide an economic benefit. For more information, visit www.quidel.com, www.colorectal-test.com, www.rsvtesting.com or www.flutest.com.

Source: Quidel Corporation

Quidel Corporation
John M. Radak, Chief Financial Officer
858-646-8032
or
Porter Novelli Life Sciences
Parag Dave, 619-849-5378
pdave@pnlifesciences.com